Stockscreener 앱 받기
8.995
2.82%
0.255
전일 마감가:
$8.74
열려 있는:
$8.94
하루 거래량:
116.83K
Relative Volume:
0.27
시가총액:
$622.40M
수익:
-
순이익/손실:
$-100.70M
주가수익비율:
-4.1261
EPS:
-2.18
순현금흐름:
$-86.54M
1주 성능:
+1.77%
1개월 성능:
-1.46%
6개월 성능:
+1.09%
1년 성능:
+26.39%
1일 변동 폭
$8.515
$9.04
1주일 범위
$8.105
$9.11
52주 변동 폭
$6.33
$16.65
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
ORIC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ORIC | 8.995 | 622.40M | 0 | -100.70M | -86.54M | -2.18 |
| VRTX | 450.63 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.04 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.57 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.97 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Perform |
| 2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-13 | 개시 | Robert W. Baird | Outperform |
| 2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Citigroup | Neutral |
| 2020-05-19 | 개시 | Guggenheim | Buy |
| 2020-05-19 | 개시 | JP Morgan | Overweight |
| 2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside - MSN
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewswire Inc.
Research Analysts Issue Forecasts for ORIC FY2024 Earnings - Defense World
Oric Pharmaceuticals Inc (ORIC-Q) QuotePress Release - The Globe and Mail
Wedbush Lowers Earnings Estimates for ORIC Pharmaceuticals - Defense World
(ORIC) Trading Advice - Stock Traders Daily
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns “Outperform” Rating from Wedbush - Defense World
Oric Pharmaceuticals Reports Strong Financial Growth and Clinical Progress - TipRanks
Alkeon Capital Management LLC's Strategic Acquisition in ORIC Ph - GuruFocus.com
Creative Planning Invests $116,000 in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
FMR LLC Reduces Stake in ORIC Pharmaceuticals Inc - GuruFocus.com
ORIC Pharmaceuticals Inc Reports Q3 2024 Net Loss of $34.6 Milli - GuruFocus.com
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates - GlobeNewswire
ORIC Pharma Secures Major J&J, Bayer Partnerships; Reports $282M Cash Position | ORIC Stock News - StockTitan
ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Buy” Rating at HC Wainwright - Defense World
ORICOric Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Long Term Trading Analysis for (ORIC) - Stock Traders Daily
Wells Fargo Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight Recommendation - MSN
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.00 - Defense World
Dermavant acquisition expands Organon’s dermatology portfolio - Pharmaceutical Technology
ORIC-114 shows promise in preclinical cancer study By Investing.com - Investing.com Australia
ORIC-114 shows promise in preclinical cancer study - Investing.com
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewswire
Analytical Overview: ORIC Pharmaceuticals Inc (ORIC)’s Ratios Tell a Financial Story - The Dwinnex
ORIC Pharmaceuticals Inc (ORIC) shows promising results - US Post News
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors - StockTitan
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
SG Americas Securities LLC Takes $714,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
The Manufacturers Life Insurance Company Buys 9,424 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Squarepoint Ops LLC Buys 16,613 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
(ORIC) Proactive Strategies - Stock Traders Daily
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
ORIC® Pharmaceuticals Announces Presentation at the - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
XTX Topco Ltd Invests $153,000 in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Profund Advisors LLC Increases Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals Inc Inc. (ORIC) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Trading Day Review: ORIC Pharmaceuticals Inc (ORIC) Loses Momentum, Closing at 10.00 - The Dwinnex
Cantor Fitzgerald Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight Recommendation - MSN
ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume Increase - Defense World
ORIC’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Brokers Set Expectations for ORIC Pharmaceuticals, Inc.’s FY2024 Earnings (NASDAQ:ORIC) - Defense World
Rhumbline Advisers Has $655,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals’ (ORIC) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Stocks of ORIC Pharmaceuticals Inc (ORIC) are poised to climb above their peers - SETE News
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Victory Capital Management Inc. - Defense World
(ORIC) On The My Stocks Page - Stock Traders Daily
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oric Pharmaceuticals Inc 주식 (ORIC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Chacko Jacob | PRESIDENT AND CEO |
Mar 06 '24 |
Sale |
16.21 |
40,000 |
648,380 |
728,544 |
| Chacko Jacob | PRESIDENT AND CEO |
Feb 07 '24 |
Sale |
12.29 |
26,042 |
320,186 |
768,544 |
| Chacko Jacob | PRESIDENT AND CEO |
Feb 06 '24 |
Sale |
12.12 |
13,958 |
169,160 |
794,586 |
| Multani Pratik S | Chief Medical Officer |
Dec 15 '23 |
Option Exercise |
0.00 |
14,042 |
0 |
29,091 |
| Multani Pratik S | Chief Medical Officer |
Dec 15 '23 |
Sale |
8.59 |
5,282 |
45,351 |
23,809 |
| Piscitelli Dominic | Chief Financial Officer |
Dec 15 '23 |
Sale |
8.58 |
5,282 |
45,338 |
83,809 |
| Chacko Jacob | President and CEO |
Dec 15 '23 |
Option Exercise |
0.00 |
38,667 |
0 |
823,083 |
| Chacko Jacob | President and CEO |
Dec 15 '23 |
Sale |
8.58 |
14,539 |
124,813 |
808,544 |
1.80%
0.42%
자본화:
|
볼륨(24시간):